当前位置： SCI文献检索 > Alzheimers Research & Therapy期刊下所有文献 > Safety and tolerability of BAN2401--a clinical study in Alzheimer's disease with a protofibril selective Aβ antibody.

Safety and tolerability of BAN2401--a clinical study in Alzheimer's disease with a protofibril selective Aβ antibody.

Abstract：

BACKGROUND:Several monoclonal antibodies for the treatment of Alzheimer's disease (AD) have been in development over the last decade. BAN2401 is a monoclonal antibody that selectively binds soluble amyloid β (Aβ) protofibrils. METHODS:Here we describe the first clinical study with BAN2401. Safety and tolerability were investigated in mild to moderate AD. A study design was used with staggered parallel single and multiple ascending doses, from 0.1 mg/kg as a single dose to 10 mg/kg biweekly for four months. The presence of amyloid related imaging abnormalities (ARIA, E for edema, H for hemorrhage) was assessed with magnetic resonance imaging (MRI). Cerebrospinal fluid (CSF) and plasma samples were analyzed to investigate pharmacokinetics (PK) and effects on biomarkers. RESULTS:The incidence of ARIA-E/H on MRI was comparable to that of placebo. BAN2401 exposure was approximately dose proportional, with a serum terminal elimination half-life of ~7 days. Only a slight increase of plasma Aβ(1-40) was observed but there were no measurable effects of BAN2401 on CSF biomarkers. On the basis of these findings Phase 2b efficacy study has been initiated in early AD. CONCLUSIONS:BAN2401 was well-tolerated across all doses. The PK profile has guided us for selecting dose and dose regimens in the ongoing phase 2b study. There was no clear guidance for an effective dose based on biomarkers. TRIAL REGISTRATION NUMBER:NCT01230853 ClinicalTrials.gov Registered October 27, 2010.

journal_name

Alzheimers Res Ther

journal_title

Alzheimer's research & therapy

authors

Logovinsky V,Satlin A,Lai R,Swanson C,Kaplow J,Osswald G,Basun H,Lannfelt L

doi

10.1186/s13195-016-0181-2

subject

Has Abstract

pub_date

2016-04-06 00:00:00

pages

14

issue

1

issn

1758-9193

pii

10.1186/s13195-016-0181-2

journal_volume

8

pub_type

临床试验,杂志文章,多中心研究,随机对照试验

相关文献

Alzheimers Research & Therapy文献大全
  • Health-related quality of life in people with predementia Alzheimer's disease, mild cognitive impairment or dementia measured with preference-based instruments: a systematic literature review.

    abstract：BACKGROUND:Obtaining reliable estimates of the health-related quality of life (HR-QoL) of people with predementia Alzheimer's disease [AD] (preclinical or prodromal AD), mild cognitive impairment (MCI) and dementia is essential for economic evaluations of related health interventions. AIMS:To provide an overview of wh...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章,评审

    doi：10.1186/s13195-020-00723-1

    authors： Landeiro F,Mughal S,Walsh K,Nye E,Morton J,Williams H,Ghinai I,Castro Y,Leal J,Roberts N,Wace H,Handels R,Lecomte P,Gustavsson A,Roncancio-Diaz E,Belger M,Jhuti GS,Bouvy JC,Potashman MH,Tockhorn-Heidenreich A,Gray

    更新日期：2020-11-18 00:00:00

  • Retinal microvasculature dysfunction is associated with Alzheimer's disease and mild cognitive impairment.

    abstract：BACKGROUND:The retina and brain share many neuronal and vasculature characteristics. We investigated the retinal microvasculature in Alzheimer's disease (AD) and mild cognitive impairment (MCI) using optical coherence tomography angiography (OCTA). METHODS:In this cross-sectional study, 24 AD participants, 37 MCI part...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/s13195-020-00724-0

    authors： Chua J,Hu Q,Ke M,Tan B,Hong J,Yao X,Hilal S,Venketasubramanian N,Garhöfer G,Cheung CY,Wong TY,Chen CL,Schmetterer L

    更新日期：2020-12-04 00:00:00

  • Long-term donepezil use for dementia with Lewy bodies: results from an open-label extension of Phase III trial.

    abstract：INTRODUCTION:The long-term efficacy and safety of donepezil 10 mg in patients with dementia with Lewy bodies (DLB) were investigated in a 52-week Phase 3 trial. METHODS:This 52-week study consisted of 16-week randomized placebo-controlled (RCT) and 36-week open-label extension phases. Of 142 DLB patients enrolled in t...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/s13195-014-0081-2

    authors： Mori E,Ikeda M,Nagai R,Matsuo K,Nakagawa M,Kosaka K

    更新日期：2015-02-03 00:00:00

  • Systemic and central nervous system metabolic alterations in Alzheimer's disease.

    abstract：BACKGROUND:Metabolic alterations, related to cerebral glucose metabolism, brain insulin resistance, and age-induced mitochondrial dysfunction, play an important role in Alzheimer's disease (AD) on both the systemic and central nervous system level. To study the extent and significance of these alterations in AD, quanti...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/s13195-019-0551-7

    authors： van der Velpen V,Teav T,Gallart-Ayala H,Mehl F,Konz I,Clark C,Oikonomidi A,Peyratout G,Henry H,Delorenzi M,Ivanisevic J,Popp J

    更新日期：2019-11-28 00:00:00

  • The dynamics of monocytes and microglia in Alzheimer's disease.

    abstract：:Alzheimer's disease (AD) is the most common neurodegenerative disorder affecting older people worldwide. It is a progressive disorder mainly characterized by the presence of amyloid-beta (Aβ) plaques and neurofibrillary tangles within the brain parenchyma. It is now well accepted that neuroinflammation constitutes an ...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/s13195-015-0125-2

    authors： Thériault P,ElAli A,Rivest S

    更新日期：2015-04-15 00:00:00

  • Communicating mild cognitive impairment diagnoses with and without amyloid imaging.

    abstract：BACKGROUND:Mild cognitive impairment (MCI) has an uncertain etiology and prognosis and may be challenging for clinicians to discuss with patients and families. Amyloid imaging may aid specialists in determining MCI etiology and prognosis, but creates novel challenges related to disease labeling. METHODS:We convened a ...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章,评审

    doi：10.1186/s13195-017-0261-y

    authors： Grill JD,Apostolova LG,Bullain S,Burns JM,Cox CG,Dick M,Hartley D,Kawas C,Kremen S,Lingler J,Lopez OL,Mapstone M,Pierce A,Rabinovici G,Roberts JS,Sajjadi SA,Teng E,Karlawish J

    更新日期：2017-05-04 00:00:00

  • The association of APOE ε4 with cognitive function over the adult life course and incidence of dementia: 20 years follow-up of the Whitehall II study.

    abstract：BACKGROUND:Approximately 25% of the general population carries at least one ε4 allele of the Apolipoprotein E (APOE ε4), the strongest genetic risk factor for late onset Alzheimer's disease. Beyond its association with late-onset dementia, the association between APOE ε4 and change in cognition over the adult life cour...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/s13195-020-00740-0

    authors： Gharbi-Meliani A,Dugravot A,Sabia S,Regy M,Fayosse A,Schnitzler A,Kivimäki M,Singh-Manoux A,Dumurgier J

    更新日期：2021-01-04 00:00:00

  • Does a prion-like mechanism play a major role in the apparent spread of α-synuclein pathology?

    abstract：:Parkinson's disease, the most common movement disorder, results in an insidious reduction for patients in quality of life and ability to function. A hallmark of Parkinson's disease is the brain accumulation of neuronal cytoplasmic inclusions comprised of the protein α-synuclein. The presence of α-synuclein brain aggre...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章,评审

    doi：10.1186/alzrt151

    authors： Sacino AN,Giasson BI

    更新日期：2012-12-17 00:00:00

  • Amyloid β-protein oligomers and Alzheimer's disease.

    abstract：:The oligomer cascade hypothesis, which states that oligomers are the initiating pathologic agents in Alzheimer's disease, has all but supplanted the amyloid cascade hypothesis, which suggested that fibers were the key etiologic agents in Alzheimer's disease. We review here the results of in vivo, in vitro and in silic...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章,评审

    doi：10.1186/alzrt226

    authors： Hayden EY,Teplow DB

    更新日期：2013-11-29 00:00:00

  • Structured relearning of activities of daily living in dementia: the randomized controlled REDALI-DEM trial on errorless learning.

    abstract：BACKGROUND:Errorless learning (EL) is a method for optimizing learning, which uses feed-forward instructions in order to prevent people from making mistakes during the learning process. The majority of previous studies on EL taught patients with dementia artificial tasks of little or no relevance for their daily lives....

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1186/s13195-017-0247-9

    authors： Voigt-Radloff S,de Werd MM,Leonhart R,Boelen DH,Olde Rikkert MG,Fliessbach K,Klöppel S,Heimbach B,Fellgiebel A,Dodel R,Eschweiler GW,Hausner L,Kessels RP,Hüll M

    更新日期：2017-03-23 00:00:00

  • A Quick Test of cognitive speed is sensitive in detecting early treatment response in Alzheimer's disease.

    abstract：INTRODUCTION:There is a great need for quick tests that identify treatment response in Alzheimer's disease (AD) to determine who benefits from the treatment. In this study, A Quick Test of cognitive speed (AQT) was compared with the mini-mental state examination (MMSE) in the evaluation of treatment outcome in AD. MET...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/alzrt53

    authors： Palmqvist S,Minthon L,Wattmo C,Londos E,Hansson O

    更新日期：2010-10-15 00:00:00

  • Brain metabolism and cerebrospinal fluid biomarkers profile of non-amnestic mild cognitive impairment in comparison to amnestic mild cognitive impairment and normal older subjects.

    abstract：INTRODUCTION:Mild cognitive impairment (MCI) is classically considered a transitional stage between normal aging and dementia. Non-amnestic MCI (naMCI) patients, however, typically demonstrate cognitive deficits other than memory decline. Furthermore, as a group, naMCI have a lower rate of an eventual dementia diagnosi...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/s13195-015-0143-0

    authors： Coutinho AM,Porto FH,Duran FL,Prando S,Ono CR,Feitosa EA,Spíndola L,de Oliveira MO,do Vale PH,Gomes HR,Nitrini R,Brucki SM,Buchpiguel CA

    更新日期：2015-09-15 00:00:00

  • The effects of different familial Alzheimer's disease mutations on APP processing in vivo.

    abstract：BACKGROUND:Disturbed amyloid precursor protein (APP) processing is considered to be central to the pathogenesis of Alzheimer's disease (AD). The autosomal dominant form of the disease, familial AD (FAD), may serve as a model for the sporadic form of AD. In FAD the diagnosis of AD is reliable and presymptomatic individu...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/s13195-017-0234-1

    authors： Thordardottir S,Kinhult Ståhlbom A,Almkvist O,Thonberg H,Eriksdotter M,Zetterberg H,Blennow K,Graff C

    更新日期：2017-02-16 00:00:00

  • Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers.

    abstract：BACKGROUND:Results from recent clinical studies suggest that cerebrospinal fluid (CSF) biomarkers that are indicative of Alzheimer's disease (AD) can be replicated in blood, e.g. amyloid-beta peptides (Aβ42 and Aβ40) and neurofilament light chain (NFL). Such data proposes that blood is a rich source of potential biomar...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/s13195-019-0545-5

    authors： Ashton NJ,Suárez-Calvet M,Heslegrave A,Hye A,Razquin C,Pastor P,Sanchez-Valle R,Molinuevo JL,Visser PJ,Blennow K,Hodges AK,Zetterberg H

    更新日期：2019-11-28 00:00:00

  • Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies.

    abstract：BACKGROUND:Development of new treatments for Alzheimer's disease (AD) has broadened into early interventions in individuals with modest cognitive impairment and a slow decline. The 11-item version of the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) was originally developed to measure cognition in ...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/s13195-016-0170-5

    authors： Podhorna J,Krahnke T,Shear M,Harrison JE,Alzheimer’s Disease Neuroimaging Initiative.

    更新日期：2016-02-12 00:00:00

  • Active immunotherapy options for Alzheimer's disease.

    abstract：:Alzheimer's disease (AD) is the most common cause of dementia and a major contributor to disability and dependency among older people. AD pathogenesis is associated with the accumulation of amyloid-beta protein (Aβ) and/or hyperphosphorylated tau protein in the brain. At present, current therapies provide temporary sy...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章,评审

    doi：10.1186/alzrt237

    authors： Winblad B,Graf A,Riviere ME,Andreasen N,Ryan JM

    更新日期：2014-01-30 00:00:00

  • ADAM10 plasma levels predict worsening in cognition of older adults: a 3-year follow-up study.

    abstract：BACKGROUND:Blood-based biomarkers for Alzheimer's disease (AD) are highly needed in clinic practice. So far, the gold standards for AD diagnosis are brain neuroimaging and beta-amyloid peptide, total tau, and phosphorylated tau in cerebrospinal fluid (CSF); however, they are not attractive for large-scale screening. Bl...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/s13195-020-00750-y

    authors： Oliveira Monteiro MPA,Salheb Oliveira DSM,Manzine PR,Crispim Nascimento CM,Dos Santos Orlandi AA,de Oliveira Gomes GA,Dos Santos Orlandi F,Zazzetta MS,Pott-Junior H,Cominetti MR

    更新日期：2021-01-08 00:00:00

  • Subjective cognitive decline and subsequent dementia: a nationwide cohort study of 579,710 people aged 66 years in South Korea.

    abstract：BACKGROUND:Subjective cognitive decline (SCD) is a potential risk factor for dementia. We aimed to investigate the association between SCD and subsequent dementia in a nationwide population-based cohort in South Korea. METHODS:This cohort included 579,710 66-year-old adults who were followed for a total of 3,870,293 p...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/s13195-020-00618-1

    authors： Lee YC,Kang JM,Lee H,Kim K,Kim S,Yu TY,Lee EM,Kim CT,Kim DK,Lewis M,Won HH,Jessen F,Myung W

    更新日期：2020-05-06 00:00:00

  • The relationship of weight change trajectory with medial temporal lobe atrophy in patients with mild Alzheimer's disease: results from a cohort study.

    abstract：INTRODUCTION:Weight loss has been described in 20% to 45% of patients with Alzheimer's disease (AD) and has been associated with adverse outcomes. Various mechanisms for weight loss in AD patients have been proposed, though none has been proven. This study aimed to elucidate a mechanism of weight loss in AD patients by...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/s13195-015-0098-1

    authors： Droogsma E,van Asselt D,Bieze H,Veeger N,De Deyn PP

    更新日期：2015-04-06 00:00:00

  • Effects of pharmacological and nonpharmacological treatments on brain functional magnetic resonance imaging in Alzheimer's disease and mild cognitive impairment: a critical review.

    abstract：BACKGROUND:A growing number of pharmacological and nonpharmacological trials have been performed to test the efficacy of approved or experimental treatments in Alzheimer disease (AD) and mild cognitive impairment (MCI). In this context, functional magnetic resonance imaging (fMRI) may be a good candidate to detect brai...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章,评审

    doi：10.1186/s13195-018-0347-1

    authors： Canu E,Sarasso E,Filippi M,Agosta F

    更新日期：2018-02-20 00:00:00

  • The monoaminergic footprint of depression and psychosis in dementia with Lewy bodies compared to Alzheimer's disease.

    abstract：INTRODUCTION:Depression and psychosis are two of the most severe neuropsychiatric symptoms (NPS) in dementia with Lewy bodies (DLB) and Alzheimer's disease (AD). Both NPS have negative effects on cognitive performance and life expectancy. The current study aimed to investigate and compare monoaminergic etiologies betwe...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/s13195-014-0090-1

    authors： Vermeiren Y,Van Dam D,Aerts T,Engelborghs S,Martin JJ,De Deyn PP

    更新日期：2015-02-11 00:00:00

  • Clinical applications of neuroimaging in patients with Alzheimer's disease: a review from the Fourth Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012.

    abstract：:In May 2012, the Fourth Canadian Consensus Conference on the Diagnosis and Treatment of Dementia brought together in Montreal experts from around Canada to update Canadian recommendations for the diagnosis and management of patients with neurodegenerative conditions associated with deterioration of cognition. Multiple...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/alzrt199

    authors： Soucy JP,Bartha R,Bocti C,Borrie M,Burhan AM,Laforce R,Rosa-Neto P

    更新日期：2013-07-08 00:00:00

  • Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer's disease.

    abstract：BACKGROUND:Down syndrome (DS), caused by chromosome 21 trisomy, is associated with an ultra-high risk of dementia due to Alzheimer's disease (AD), driven by amyloid precursor protein (APP) gene triplication. Understanding relevant molecular differences between those with DS, those with sporadic AD (sAD) without DS, and...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/s13195-019-0477-0

    authors： Startin CM,Ashton NJ,Hamburg S,Hithersay R,Wiseman FK,Mok KY,Hardy J,Lleó A,Lovestone S,Parnetti L,Zetterberg H,Hye A,LonDownS Consortium.,Strydom A

    更新日期：2019-03-21 00:00:00

  • Progression to dementia in memory clinic patients with mild cognitive impairment and normal β-amyloid.

    abstract：BACKGROUND:Determination of β-amyloid (Aβ) positivity and likelihood of underlying Alzheimer's disease (AD) relies on dichotomous biomarker cut-off values. Individuals with mild cognitive impairment (MCI) and Aβ within the normal range may still have a substantial risk of developing dementia, primarily of Alzheimer typ...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/s13195-019-0557-1

    authors： Rosenberg A,Solomon A,Jelic V,Hagman G,Bogdanovic N,Kivipelto M

    更新日期：2019-12-05 00:00:00

  • Subcortical hyperintensity volumetrics in Alzheimer's disease and normal elderly in the Sunnybrook Dementia Study: correlations with atrophy, executive function, mental processing speed, and verbal memory.

    abstract：INTRODUCTION:Subcortical hyperintensities (SHs) are radiological entities commonly observed on magnetic resonance imaging (MRI) of patients with Alzheimer's disease (AD) and normal elderly controls. Although the presence of SH is believed to indicate some form of subcortical vasculopathy, pathological heterogeneity, me...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/alzrt279

    authors： Ramirez J,McNeely AA,Scott CJ,Stuss DT,Black SE

    更新日期：2014-08-11 00:00:00

  • Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease.

    abstract：:Autosomal-dominant Alzheimer's disease has provided significant understanding of the pathophysiology of Alzheimer's disease. The present review summarizes clinical, pathological, imaging, biochemical, and molecular studies of autosomal-dominant Alzheimer's disease, highlighting the similarities and differences between...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/alzrt59

    authors： Bateman RJ,Aisen PS,De Strooper B,Fox NC,Lemere CA,Ringman JM,Salloway S,Sperling RA,Windisch M,Xiong C

    更新日期：2011-01-06 00:00:00

  • Alzheimer's disease phospholipase C-gamma-2 (PLCG2) protective variant is a functional hypermorph.

    abstract：BACKGROUND:Recent Genome Wide Association Studies (GWAS) have identified novel rare coding variants in immune genes associated with late onset Alzheimer's disease (LOAD). Amongst these, a polymorphism in phospholipase C-gamma 2 (PLCG2) P522R has been reported to be protective against LOAD. PLC enzymes are key elements ...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/s13195-019-0469-0

    authors： Magno L,Lessard CB,Martins M,Lang V,Cruz P,Asi Y,Katan M,Bilsland J,Lashley T,Chakrabarty P,Golde TE,Whiting PJ

    更新日期：2019-02-02 00:00:00

  • HHV-6A infection induces amyloid-beta expression and activation of microglial cells.

    abstract：BACKGROUND:The control of viral infections in the brain involves the activation of microglial cells, the macrophages of the brain that are constantly surveying the central nervous system, and the production of amyloid-beta (Aβ) as an anti-microbial molecule. Recent findings suggest a possible implication of HHV-6A in A...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/s13195-019-0552-6

    authors： Bortolotti D,Gentili V,Rotola A,Caselli E,Rizzo R

    更新日期：2019-12-12 00:00:00

  • Utility of the Dependence Scale in dementia: validity, meaningfulness, and health economic considerations.

    abstract：BACKGROUND:The concept of dependence has been proposed as a unified representation of disease severity to quantify and stage disease progression in a manner more informative to patients, caregivers, and healthcare providers. METHODS:This paper provides a review of the Dependence Scale (DS) as a quantitative measure of...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章,评审

    doi：10.1186/s13195-018-0414-7

    authors： Zhu CW,Bruinsma BG,Stern Y

    更新日期：2018-08-13 00:00:00

  • Have we learnt all we need to know from genetic studies - is genetics over in Alzheimer's disease?

    abstract：BACKGROUND:Alzheimer's disease (AD) pathophysiology is mostly (>95%) not inherited in a Mendelian fashion. Such sporadic AD (sAD) forms do not exhibit familial aggregation and are characterized by complex genetic inheritance. Growing evidence indicates that multiple genes contribute to sAD-characteristic endophenotypes...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/alzrt165

    authors： Hampel H,Lista S

    更新日期：2013-03-18 00:00:00